Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | Promising agents being explored in R/R MCL: bispecific antibodies and BTK inhibitors

Marcus Messmer • 16 Jun 2023
ICML 2023
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Antibodies BTK inhibitors Glofitamab Obinutuzumab Pirtobrutinib Venetoclax Zanubrutinib
BOVen

Marcus Messmer, MD, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, discusses promising agents being explored for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL), drawing focus on glofitamab and pirtobrutinib. Dr Messmer also comments on the excitement around the BOVen trial (NCT03824483), which is evaluating zanubrutinib, obinutuzumab, and venetoclax in patients with TP53-mutated MCL. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Marcus Messmer

1:36
The impact of TP53 mutation on treatment approaches in MCL
Marcus Messmer • 16 Jun 2023
2:48
Outcomes of autoSCT, alloSCT & CAR-T cell therapy in patients with TP53-altered MCL
Marcus Messmer • 16 Jun 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals